Insight

Targeting serine/glycine metabolism with sertraline can enhance radiotherapy responses in NSCLC – ESTRO

Photo taken from ESTRO/LinkedIn

Aug 11, 2024, 13:07

Targeting serine/glycine metabolism with sertraline can enhance radiotherapy responses in NSCLC – ESTRO

European Society for Radiotherapy and Oncology (ESTRO) shared on LinkedIn:

“Pre-clinical findings presented at ESTRO24 reveal that targeting serine/glycine metabolism with sertraline can enhance radiotherapy responses in NSCLC (non-small cell lung cancer). This approach radiosensitises the tumor and reduces immune suppression.”

What is Non-Small Cell Lung Cancer? | Charles River

Read further.
Source: ESTRO/LinkedIn

cancer ESTRO European SocieTy for Radiotherapy and Oncology immune suppression non small cell lung cancer NSCLC OncoDaily Oncology radiosensitises serine/glycine metabolism sertraline

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Richard Sullivan: Do we need a 'new' Geneva Convention and protocols?

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Special Coverage